BWAY
Get informed when a big investor buys or sells
+ FollowOvervalued by 73.8% based on the discounted cash flow analysis.
| Market cap | $543.78 Million |
|---|---|
| Enterprise Value | $498.74 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.4 |
| Beta | 0.15 |
| Outstanding Shares | 20,064,705 |
| P/E Ratio | 55.81 |
|---|---|
| PEG | 169.48 |
| Price to Sales | 4.54 |
| Price to Book Ratio | 3.41 |
| Enterprise Value to Revenue | 7.68 |
| Enterprise Value to EBIT | 98.67 |
| Enterprise Value to Net Income | 49 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.22 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 11,000▲ Infinity% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 56.86%▼ 4.52% |
|---|---|
| Total Invested | $176.89M▲ 13.66% |
| Investors Holding | 58▲ 2.00% |
No data
Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the tr...